Patent ID: 8097260

Claim:
A method of eliciting an immune response in a subject against Neisseria meningitidis comprising administering to the subject a pharmaceutical composition comprising (a) a Neisseria meningitidis cell comprising a disrupted msbB gene, wherein the cell has a reduced amount of lipooligosaccharide (LOS) present in the cell's outer membrane and/or lipid A components present in the cell's outer membrane as compared to the corresponding wild-type Neisseria meningitidis cell, wherein the msbB gene is disrupted by mutagenesis, wherein the cell is Neisseria meningitidis NMBA11K3 cell having ATCC designation PTA-7257 or its acapsular mutant NMBA11K3cap-; and (b) a pharmaceutically acceptable carrier, wherein the composition is capable of eliciting an immune response against Neisseria meningitidis.